Comorbidity Studies

ME/CFS rarely occurs in isolation. Comorbid conditions are the rule rather than the exception, and their recognition and treatment is a clinical priority (Section Critical Principle: Aggressive Management of All Comorbidities).

1 Patterns of Comorbid Conditions

The most frequently co-occurring conditions form a recognizable cluster:

  • Fibromyalgia: 50–70% overlap. Shared features include widespread pain, fatigue, cognitive dysfunction, and sleep disturbance. Whether fibromyalgia and ME/CFS represent distinct entities or overlapping phenotypes of a common pathophysiology remains debated
  • Postural orthostatic tachycardia syndrome (POTS): 50–70% prevalence in ME/CFS cohorts. POTS may develop concurrently with or subsequent to ME/CFS onset
  • Mast cell activation syndrome (MCAS): Estimated 15–30% prevalence, likely underdiagnosed (Wirth and Scheibenbogen 2023). MCAS explains many of the “allergic” and inflammatory symptoms in ME/CFS
  • Hypermobile Ehlers-Danlos syndrome (hEDS): Elevated co-occurrence, potentially reflecting shared connective tissue and autonomic dysfunction. The ME/CFS–POTS–hEDS–MCAS tetrad is increasingly recognized as a distinct clinical phenotype
  • Irritable bowel syndrome (IBS): 50–60% prevalence. Reflects autonomic GI dysfunction and gut barrier impairment
  • Migraine: 30–50% prevalence, potentially related to neuroinflammation and autonomic dysfunction
  • Endometriosis: Women with endometriosis have 2.79-fold higher odds of developing ME/CFS (OR 2.79, 95% CI 2.00–3.89; pooled OR 2.52, 95% CI 2.45–2.60 across 13 studies, \(n\) up to 134,805) (Compton et al. 2025). ME/CFS prevalence in endometriosis patients is approximately 17%, and endometriosis prevalence in ME/CFS patients approximately 13%. Shared mechanisms are likely to include chronic immune activation, mast cell involvement, and neuroinflammatory features—both conditions involve dysregulated immune tolerance. Importantly, 54% of included studies relied on self-reported endometriosis, and prevalence heterogeneity is extreme (\(I^2 > 98\\%\)), warranting caution in applying population estimates to individual patients
  • Interstitial cystitis/painful bladder syndrome: Elevated prevalence, part of the central sensitization spectrum

2 Temporal Relationships

Comorbidities may precede, coincide with, or develop after ME/CFS onset:

  • Pre-existing: hEDS, MCAS, and migraine often predate ME/CFS onset, suggesting they may represent predisposing factors or shared vulnerability
  • Concurrent onset: POTS and fibromyalgia frequently develop alongside ME/CFS, often triggered by the same infectious event
  • Secondary development: IBS, depression, and anxiety typically develop after ME/CFS onset and may represent consequences of the disease or its associated physiological disruption
  • Progressive accumulation: Many patients report accumulating additional diagnoses over time, consistent with progressive multi-system dysfunction

3 Shared Mechanisms

The clustering of comorbidities in ME/CFS suggests shared underlying mechanisms rather than coincidental co-occurrence (see Chapter Integrative Models and Multi-System Pathophysiology for detailed models):

  • Autonomic dysfunction: A common denominator linking POTS, IBS, temperature dysregulation, and bladder dysfunction
  • Central sensitization: May underlie fibromyalgia, migraine, IBS, and interstitial cystitis
  • Immune dysregulation: Connects MCAS, autoimmune features, and chronic inflammation
  • Connective tissue abnormality: hEDS-associated tissue laxity may contribute to vascular compliance issues (POTS), visceral hypermobility (IBS), and joint instability
  • Neuroinflammation: May simultaneously produce cognitive dysfunction, pain, autonomic instability, and mood disturbance

References

Compton, Sabrina, Rodolf Alkabalan, Judd Cadet, Azin Mastali, and Prakash V A K Ramdass. 2025. “Endometriosis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review and Meta-Analysis.” Diagnostics 15 (18): 2332. https://doi.org/10.3390/diagnostics15182332.
Wirth, Klaus, and Carmen Scheibenbogen. 2023. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Comorbidities: Linked by Vascular Pathomechanisms and Vasoactive Mediators?” Healthcare 11 (7): 978. https://doi.org/10.3390/healthcare11070978.